Astex Pharmaceuticals Management Discusses Q2 2012 Results - Earnings Call Transcript

Astex Pharmaceuticals (ASTX)

Q2 2012 Earnings Call

July 30, 2012 4:30 pm ET

Executives

Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications

James S. J. Manuso - Chairman and Chief Executive Officer

Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary

Mohammad Azab - Chief Medical Officer

Analysts

Boris Peaker - Oppenheimer & Co. Inc., Research Division

Robin Davison - Edison Investment Research Limited

George B. Zavoico - McNicoll, Lewis & Vlak LLC, Research Division

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Astex Pharmaceuticals Quarter 2 2012 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the call over to your host for today, Mr. Timothy Enns, Senior Vice President, Corporate Communications and Marketing. Sir, you may begin.

Timothy L. Enns

Thank you, operator. Good day, and thank you for joining us for Astex Pharmaceuticals 2012 Second Quarter Financial Results Conference Call. With me today are Dr. James Manuso, Chairman and Chief Executive Officer; Dr. Harren Jhoti, President and member of the Board of Directors; Dr. Mohammad Azab, Chief Medical Officer; Dr. Martin Buckland, Chief Business Officer; and Michael Molkentin, Chief Financial Officer. In a few moments, Jim Manuso and Michael Molkentin will deliver remarks on the 2012 second quarter financial results and our business outlook for the year. After prepared comments, we will open the line for questions. Earlier today, we issued a press release with our financial results. A copy of the press release is available in the Investor Relations section of our website at www.astx.com.

If you liked this article you might like

Trade-Ideas: Astex Pharmaceuticals (ASTX) Is Today's Pre-Market Mover With Heavy Volume Stock

Biotech Stock Mailbag: Astex Pharma, My Essential Twitter Follows

Trade-Ideas: Astex Pharmaceuticals (ASTX) Is Today's "Perilous Reversal" Stock

4 Biotech Stocks Under $10 to Trade for Breakouts

Astex Pharmaceuticals Inc Stock Downgraded (ASTX)